Open-label Study in Patients With Metastatic NSLC Treated With Cisplatin, Gemcitabine and Bevacizumab

OBJECTIVES

Primary objective:

• To assess early tumour response (at day +7) in terms of blood flow as compared to Objective Response Rate (ORR) in terms of RECIST criteria (CR + PR) at day 42.

Secondary objectives:

• To assess early tumour response (at day +7) in terms of blood volume, mean transit time, enhancement peak, time to the enhancement peak and capillary tumour permeability as compared to ORR (CR + PR) at day 42.
• To assess tumour response (at day +42) in terms of blood flow, blood volume, mean transit time, enhancement peak, time to the enhancement peak and capillary tumour permeability as compared to ORR (CR + PR) at day 42.
• To assess tumour response (at day +7 and +42) in terms of blood flow, blood volume, mean transit time, enhancement peak, time to the enhancement peak and capillary tumour permeability as compared to PFS and OS
• Safety profile using NCI-CTC AE (version 4.0).
• To assess the efficacy in the subgroup of adenocarcinoma pts.

Outline:

Patients receive bevacizumab 7.5mg/kg IV, cisplatin 80mg/m2 and gemcitabine 1250 mg/m2 on days 1 and 8 up to 6 cycles of 21 days. Patients without progression may continue maintenance treatment with single-agent bevacizumab 7.5 mg/Kg on day 1 every 21 days.

Inclusion criteria

• Give the written informed consent to participate in the trial before carrying out any specific study procedure.
• Histological or cytological non microcytic lung cancer (NMLC) and non squamous advanced locally or metastatic (IIIB/IV) lung cancer confirmation
• Capability to take on the obligations with study protocol requirements.
• Patients 18 years old.
• ECOG functional status 0 or 1.
• At least a measurable lung lesion with conventional TAC (i.e. ≥ 1cm) in at least one dimension its RECIST criteria (v.1.1) which has not been irradiated.
• Appropriate bone marrow function.
• Appropriate hepatic function.

• International normalized ratio (INR) ≤ 1.5 and activate partial thromboplastin time (aPTT) ≤ 1.5 x UNL 7 days previous to the first study drug administration, unless patients have been used prophylactic anticoagulant treatment 11. Patients with brain metastasis which had been treated and also asymptomatic , they are eligible to participate in the study.

• Female patients cannot be pregnant nor lactating. 13. Male fertile patients have to use a high effective method of contraception.

Exclusion criteria

• Previous treatment with systemic chemotherapy for advance NMLC
• Non microcytic- microcytic mix histology or adeno-squamous mix carcinomas with a predominant squamous component
• Hemoptysis history ≥ grade 2 (defined as at least 2.5 ml of bright red blood) in a period of 3 months prior to receive the study drugs
• Surgery (including open biopsy) or significant traumatic injury in a period of 28 day prior to receive the study drugs.
• Minor surgery including a catheter insertion in a period of 24h prior to the first infusion of bevacizumab
• Proof that the tumor can compress or invade a main vessel in image tests
• Radiotherapy in any site for any reason in a period of 28 days prior to receive the study drugs. It is permitted palliative radiotherapy to bone lesions .
• Aspirin based medication (> 325 mg/day or clopidogrel > 75mg/day) present or recent (in a period of 10 days from the first bevacizumab infusion). Medication with oral anticoagulants agents or parenteral medication on full doses (e.g. in a therapeutic range) or the use of thrombolytic agents with present and recent therapeutic intentions (in a period of 10 days prior to the first bevacizumab infusion). The prophylactic medication with anticoagulants is permitted
• History or evidence of inheritance bleeding diathesis or coagulopathy with bleeding risk
• Active gastrointestinal bleeding
• Inadequate controlled hypertension .
• Cardiovascular disease .
• Wounds that do not heal, active peptide ulcer or non treated bone fractures.
• History of abdominal fistula, gastrointestinal perforation or intra-abdominal abscess in the 6 months prior to receive the study drugs
• Known hypersensitivity to bevacizumab, cisplatin or gemcitabine or any of its excipients
• Important known hypersensitivity to iodated contrast agents
• Another neoplastic disease other than NMLC in a period of 5 years prior to receive the study drugs with exemption of in situ cervix carcinoma, basal or squamous skin cancer, prostate cancer treated with curative intention and in situ breast ductal carcinoma treated with curative intention
• Proof of any other disease, neurologic or metabolic dysfunction, lab abnormality or physical test that can reasonably make suspect circumstances that would contraindicate the use of a certain investigational or the standard treatment used in this study or that puts the patient into a greater risk to suffer complications related to the treatment